Skip to main content
Pharmicell Co.,Ltd. logo

Pharmicell Co.,Ltd. — Investor Relations & Filings

Ticker · 005690 ISIN · KR7005690003 KO Manufacturing
Open in API
Filings indexed 275 across all filing types
Latest filing 2019-12-02 Regulatory Filings
Country KR South Korea
Listing KO 005690

About Pharmicell Co.,Ltd.

https://www.pharmicell.com/eng/

Pharmicell Co., Ltd. is a biopharmaceutical company specializing in stem cell technology and advanced bio-based materials. The company is a pioneer in regenerative medicine, having developed Hearticellgram-AMI, the world's first approved stem cell therapy for acute myocardial infarction. Its core business includes the development of stem cell therapeutics, a stem cell banking service for adult and cord blood cells, and a line of cosmetics based on stem cell culture media. A significant division focuses on fine chemicals, manufacturing and supplying critical raw materials for the pharmaceutical industry, such as nucleosides, mPEGs, and oligonucleotides for gene therapies. The company also produces eco-friendly flame retardants for industrial use.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(특허권 취득)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from Pharmicell regarding the acquisition of a patent ('특허권 취득'). It follows the standard format for a 'Major Management Matter' (주요경영사항) disclosure in the Korean market, which is used to inform investors of significant corporate events that do not fit into financial reporting categories. Since it is a specific regulatory disclosure of a material event, it falls under the RNS (Regulatory Filings) category.
2019-12-02 Korean
분기보고서 (2019.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Pharmicell Co., Ltd. covering the period from January 1, 2019, to September 30, 2019. It contains detailed company information, business descriptions, capital changes, and financial data structures typical of a formal quarterly filing submitted to the Financial Services Commission and Korea Exchange. It is not an announcement of a report, but the report itself. 9M 2019
2019-11-12 Korean
반기보고서 (2019.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for Pharmicell Co., Ltd., covering the period from January 1, 2019, to June 30, 2019. It contains detailed company information, business descriptions, capital changes, and financial data structures typical of a formal interim financial report filed with the Financial Services Commission and the Korea Exchange. It is not a mere announcement or certification, but the full report itself. H1 2019
2019-08-12 Korean
[기재정정]사업보고서 (2018.12)
Annual Report Classification · 95% confidence The document is a 'Correction Report' (정정신고) for a previously filed Annual Report (사업보고서). It explicitly details corrections made to financial statements (Balance Sheet, Income Statement, Cash Flow, etc.) due to accounting errors regarding development cost impairment. Since it contains substantive financial data and restated financial statements for multiple fiscal years, it functions as a financial report update rather than a simple announcement. In the context of Korean regulatory filings (DART), this is a formal amendment to an annual report. FY 2018
2019-07-18 Korean
회계처리기준위반에따른임원의해임권고조치
Legal Proceedings Report Classification · 95% confidence The document is an official regulatory announcement regarding a Securities and Futures Commission (SFC) enforcement action against Pharmicell for accounting violations. It details specific sanctions, including the recommendation to dismiss an executive (the CFO/Financial Management Head) and an auditor, as well as financial restatements. Since this document reports on legal/regulatory enforcement actions and penalties, it falls under the 'Legal Proceedings Report' category.
2019-06-14 Korean
분기보고서 (2019.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Pharmicell Co., Ltd., covering the period from January 1, 2019, to March 31, 2019. It contains detailed company information, business overview, capital changes, and financial data structures typical of a formal quarterly filing submitted to the Financial Supervisory Service (FSS) and Korea Exchange (KRX). It is not an announcement of a report, but the report itself. Q1 2019
2019-05-09 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.